Turkey's c. bank to maintain current rates until Q4    Egypt's gold prices slightly down on Wednesday    Tesla to incur $350m in layoff expenses in Q2    GAFI empowers entrepreneurs, startups in collaboration with African Development Bank    Egyptian exporters advocate for two-year tax exemption    Egyptian Prime Minister follows up on efforts to increase strategic reserves of essential commodities    Italy hits Amazon with a €10m fine over anti-competitive practices    Environment Ministry, Haretna Foundation sign protocol for sustainable development    After 200 days of war, our resolve stands unyielding, akin to might of mountains: Abu Ubaida    World Bank pauses $150m funding for Tanzanian tourism project    China's '40 coal cutback falls short, threatens climate    Swiss freeze on Russian assets dwindles to $6.36b in '23    Amir Karara reflects on 'Beit Al-Rifai' success, aspires for future collaborations    Ministers of Health, Education launch 'Partnership for Healthy Cities' initiative in schools    Egyptian President and Spanish PM discuss Middle East tensions, bilateral relations in phone call    Amstone Egypt unveils groundbreaking "Hydra B5" Patrol Boat, bolstering domestic defence production    Climate change risks 70% of global workforce – ILO    Health Ministry, EADP establish cooperation protocol for African initiatives    Prime Minister Madbouly reviews cooperation with South Sudan    Ramses II statue head returns to Egypt after repatriation from Switzerland    Egypt retains top spot in CFA's MENA Research Challenge    Egyptian public, private sectors off on Apr 25 marking Sinai Liberation    EU pledges €3.5b for oceans, environment    Egypt forms supreme committee to revive historic Ahl Al-Bayt Trail    Debt swaps could unlock $100b for climate action    Acts of goodness: Transforming companies, people, communities    President Al-Sisi embarks on new term with pledge for prosperity, democratic evolution    Amal Al Ghad Magazine congratulates President Sisi on new office term    Egypt starts construction of groundwater drinking water stations in South Sudan    Egyptian, Japanese Judo communities celebrate new coach at Tokyo's Embassy in Cairo    Uppingham Cairo and Rafa Nadal Academy Unite to Elevate Sports Education in Egypt with the Introduction of the "Rafa Nadal Tennis Program"    Financial literacy becomes extremely important – EGX official    Euro area annual inflation up to 2.9% – Eurostat    BYD، Brazil's Sigma Lithium JV likely    UNESCO celebrates World Arabic Language Day    Motaz Azaiza mural in Manchester tribute to Palestinian journalists    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Egypt's Eva Pharma begins manufacturing of COVID-19 drug approved by Russia
Ahram Online Published in Ahram Online on 23 - 06 - 2020

Egyptian drugmaker Eva Pharma said it has begun manufacturing antiviral treatment Avipiravir, which has proved effective in treating COVID-19 patients in Russia amid ongoing trials of the same drug in Japan and other countries.
The company has begun producing the drug at its factories in Egypt after conducting necessary manufacturing trials, Riad Armanious, CEO of Eva Pharma, said a statement sent to Ahram Online late on Monday. The company is coordinating with relevant Egyptian authorities to make the drug available for treating the highly contagious virus in the coming period, he added.
The Egyptian drug would contain the active substance of Favipiravir, an oral antiviral drug originally approved for the treatment of influenza in Japan. It is currently being tested to treat COVID-19 under different brand names in Japan and other countries.
Armanious said Eva Pharma aims to meet local demand of the drug, as well as export it to a number of countries in the Middle East, Africa and beyond.
Russia started using the drug, known there as Avifavir, earlier this month -- its first treatment approved to treat COVID-19 patients -- after clinical trials had shown it successfully treated the virus in most cases within a few days.
The announcement by Eva Pharma comes nearly a week after the pharmaceutical company reached a “landmark” deal with Gilead Sciences Inc to become a licensed manufacturer of the US company's antiviral treatment remdesivir for COVID-19 in 127 countries.
Remdesivir, originally developed to treat Ebola, appears to shorten the recovery time of COVID-19 patients. The experimental drug has recently been authorised for the treatment of certain hospitalised patients in a number of countries including the US, the UK and Japan.
The Egyptian drug manufacturer is waiting for registration approval by Egypt's health authorities, after which the medicine will be ready for sale, a source at the company told Ahram Online last week.
No vaccine for COVID-19 has yet been developed, and many countries are conducting human trials of several existing antiviral drugs to prove their efficacy.

Clic here to read the story from its source.